Camp4 Therapeutics Corp
CAMP evidence brief
What we can confirm
- BioSniper Score:
- 5.9 / 10
- Market Cap:
- $266.7M
What it means
What to watch
Prepared research question
What matters most for CAMP—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CAMP
Camp4 Therapeutics Corp (CAMP) is a clinical-stage biopharmaceutical company developing regulatory RNA-targeting therapeutics to upregulate gene expression for genetic diseases, with its lead candidate CMP-002 entering Phase 1/2 trials for SYNGAP1-related disorder.
Key risk: Negative equity
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$266.7M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 clinical trial for Camp4 Therapeutics Corp.
Camp4 Therapeutics Corp (CAMP) is a clinical-stage biopharmaceutical company developing regulatory RNA-targeting therapeutics to upregulate gene expression for genetic diseases, with its lead candidate CMP-002 entering Phase 1/2 trials for SYNGAP1-related disorder.
- Cash & equivalents of $86.4M as of 2026-06-30 [sec].
- Total revenue of $1.8M and net income of -$33.5M as of 2026-06-30 [sec].
- Shareholders' equity of -$0.7M as of 2026-06-30 [sec].
- Lead candidate CMP-002 has received regulatory clearance in Australia, Argentina, and the UK for a Phase 1/2 clinical trial (ASCEND) in SYNGAP1-related disorder, with first patient dosing expected by end of 2026 [sec · filed 2026-09-28].
- The company expects a topline data readout from the ASCEND trial in the first half of 2028 [sec · filed 2026-09-28].
What works
- Cash runway extended through end of 2028, supported by $50.1M from a fully subscribed second closing of a private placement [news · published 2026-08-13].
- Regulatory clearances in multiple jurisdictions (Australia, Argentina, UK) for first-in-human trial of CMP-002, indicating progress in clinical development [news · published 2026-09-10].
- Proprietary RAP Platform enables identification of regulatory RNAs (regRNAs) to upregulate gene expression, providing a differentiated approach to treating genetic diseases [sec · filed 2026-08-06].
What to weigh
- Net income of -$33.5M and negative shareholders' equity of -$0.7M as of 2026-06-30 indicate ongoing operating losses and a negative equity position [sec].
- Total revenue of only $1.8M as of 2026-06-30 reflects a pre-commercial stage with no approved products generating significant sales [sec].
- The lead candidate CMP-002 is still in early Phase 1/2 testing, with topline data not expected until first half of 2028, meaning years of development and regulatory risk remain [sec · filed 2026-09-28].
From the filings
Quoted directly from source documents.
Cash position and financial runway
“Cash runway extended through the end of 2028.”
News · August 13, 2026
Regulatory clearance for CMP-002 trial in UK
“Authorization from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) builds on CAMP4’s recent clearances to initiate first-in-human studies for CMP-002 in Australia and Argentina”
News · September 10, 2026
Expected first patient dosing and data readout for ASCEND trial
“The Company expects to dose the first patient in the ASCEND clinical trial by the end of 2026. The Company is targeting a topline data readout from the ASCEND clinical trial in the first half of 2028.”
SEC filings · September 28, 2026
Proprietary platform technology
“Our product development efforts are enabled by our proprietary RAP Platform. We leverage our RAP Platform to identify and characterize regulatory RNAs ("regRNAs"), which play a central role in the regulation of every protein-coding gene”
SEC filings · August 6, 2026
Risks & what to watch (3)›
Key risks
- Negative equity — Shareholders' equity of -$0.7M as of 2026-06-30 indicates liabilities exceed assets [sec].
- Early-stage pipeline
- Minimal revenue
What to watch
- Initiation of the Phase 1/2 ASCEND clinical trial for CMP-002, expected first patient dosing by end of 2026 [sec · filed 2026-09-28].
- Topline data readout from the ASCEND trial, targeted for first half of 2028 [sec · filed 2026-09-28].
- Progress of preclinical program targeting SHANK3 for Phelan-McDermid Syndrome [sec · filed 2026-09-28].
- Cash runway and any future financing needs, as current runway extends through end of 2028 [news · published 2026-08-13].
Sources: News · SEC filings · SEC MD&A · Generated October 4, 2026 · How we verify sources →
Run Camp4 Therapeutics Corp through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Camp4 Therapeutics Corp facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
Net income -$34M
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
5 buys · 4 sells (180d)
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
46
Total value held
$175.4M
| Holder | Shares | Value |
|---|---|---|
| janus henderson group plc | 6,307,636 | $27.9M |
| 5am venture management, llc | 5,869,091 | $25.9M |
| fmr llc | 4,933,432 | $21.8M |
| vivo capital, llc | 4,246,568 | $18.7M |
| balyasny asset management l.p. | 2,632,437 | $11.6M |
| enavate sciences gp, llc | 2,190,920 | $9.7M |
| a16z capital management, l.l.c. | 2,125,339 | $9.4M |
| adage capital partners gp, l.l.c. | 1,960,784 | $8.6M |
| trails edge capital partners, lp | 1,939,563 | $8.6M |
| vanguard capital management llc | 1,534,768 | $6.8M |
Showing top 10 of 46 institutional holders of Camp4 Therapeutics Corp. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 1.3%
- Days to cover
- 6.0
- Shares short
- 450,462
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CAMP short interestGovernance
Frequently asked questions
What is the AI investment thesis for Camp4 Therapeutics Corp?
Camp4 Therapeutics Corp (CAMP) is a clinical-stage biopharmaceutical company developing regulatory RNA-targeting therapeutics to upregulate gene expression for genetic diseases, with its lead candidate CMP-002 entering Phase 1/2 trials for SYNGAP1-related disorder.
Who is the CEO of Camp4 Therapeutics Corp?
Mr. Joshua Mandel-Brehm is the chief executive officer of Camp4 Therapeutics Corp (CAMP).
Where is Camp4 Therapeutics Corp headquartered?
Camp4 Therapeutics Corp (CAMP) is headquartered in Cambridge, MA, United States.
What therapeutic areas does Camp4 Therapeutics Corp focus on?
Camp4 Therapeutics Corp develops therapies across Neurology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.